{"version":"1.0","type":"link","title":"Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.","author_name":"Filippi AR 외","author_url":"https://prs-insight.online/author/Filippi%20AR","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/101351","thumbnail_width":1200,"thumbnail_height":630}